SUMMARY: For most patients, the HIV viral load can be made undetectable by highly active retroviral treatments (HAART); the virus however cannot be eradicated. Thus, the major problem is to try to reduce the side effects of the treatment that patients have to take during their life time. We tackle the problem of monitoring the treatment dose, with the aim of giving the minimum dose that yields an undetectable viral load. The approach is based on mechanistic models of the interaction between virus and the immune system. It is shown that the "activated cells model", allows making good predictions of the effect of dose changes and thus could be a good basis for treatment monitoring. Then, we use the fact that in dynamical models there is a non-trivial equilibrium point, that is with a virus load larger than zero, only if the reproductive number R0 is larger than one. For reducing side effects we may give a dose just above the critical dose corresponding to R0 = 1. A prior distribution of the parameters of the model can be taken as the posterior arising from the analysis of previous clinical trials. Then the observations for a given patient can be used to dynamically tune the dose so that there is a high probability that the reproductive number is below one. The advantage of the approach is that it does not depend on a cost function, weighing side effects and efficiency of the drug. It is shown that it is possible to approach the critical dose if the model is correct. A sensitivity analysis assesses the robustness of the approach.
Introduction
In developed countries, most HIV infected patients are treated with highly active antiretroviral therapies (HAART), which include a combination of several antiretroviral drugs. For many patients, such treatments succeed to control viral replication (i.e., the viral load becomes undetectable) and to restore the immune system sufficiently to dramatically decrease the risk of opportunistic diseases and AIDS (Egger et al., 2002) . The virus is however still present in sanctuaries like resting memory cells (Chomont et al., 2009) . Several side effects have been described in patients having long-term therapy (Carr and Cooper, 2000) . To reduce these side effects, treatment interruptions have been attempted. However, these trials have been stopped at interim analysis showing an increased risk of opportunistic diseases (Ananworanich et al., 2006; Danel et al., 2006; Lundgren et al., 2008) .
Attempts have been made to decrease the number of drugs but did not succeed either (Girard et al., 2009) . Reducing the doses of treatment may be a flexible way to alleviate side effects while maintaining efficiency (Sánchez-Conde et al., 2005; Milinkovic et al., 2007; Meynard et al., 2010) .
These studies however proposed an arm-specific reduction (same reduction for every patient from the same arm). A subject-specific dose adaptation (dose individualization) will probably lead to more significant results.
Recently, adaptive treatment strategies have been proposed in the statistical literature (Murphy, 2003; Murphy and McKay, 2004; Moodie et al., 2007; Lavori and Dawson, 2008; Henderson et al., 2010) . These approaches adapt some concepts of control theory, in particular dynamic programming, developed in engineering (Sage and White, 1977) . In engineering, dynamical models on which optimal control is based are more complex than those generally used for adaptive treatment strategies and they are often expressed through a system of differential equations. Kirschner et al. (1997) proposed to use control theory based on mechanistic models of the interaction of HIV and the immune system for adapting the dose of antiretroviral treatment. Indeed since the pioneering work of Ho et al. (1995) and Wei et al. (1995) , several mechanistic models have been developed. However, treatment monitoring raises different issues than control problems in engineering and the estimation of parameters in HIV dynamics models is challenging. Recent statistical approaches use random effect models with the aim to estimate the parameters of complex models using rather large samples from clinical trials: see Wu (2005) for a review and Putter et al. (2002) ; Huang et al. (2006) ; Guedj et al. (2007) ; Huang et al. (2010) among others for original developments.
The aim of this paper is to examine the possibility of using such sophisticated mechanistic models, with parameters that can be estimated on previous clinical trial data, for monitoring the treatment dose of an individual patient. A Bayesian approach seems here natural (Berger, 1985) .
Previous data give a prior for the parameters of the model. Observations for a new patient give additional information, especially on parameters varying between patients, and permit to update the priors. Then the dose can be adapted so as to minimize a risk function. One key idea in this paper is that, for reasonable risk functions, the target dose is the critical dose which makes the reproductive number R 0 equal to (or just below) one. After presenting the method we shall examine whether it can work in real life. This is a "proof of concept" paper: real patients have not yet taken doses recommended by our method but we give arguments to convince that mechanistic models, and this particular method, can be used for treatment monitoring. We first examine, using real data, whether our model can detect an influence of the treatment dose; then we examine the predictive ability of the model, still using real data. Then we apply the control method on simulated data. The paper is organized as follows. Section 2 recalls the mathematical and statistical models developed by Guedj et al. (2007) and Drylewicz et al. (2010) . Section 3 tackles the control problem first treating the case with known parameters, then the case with unknown parameters. The optimal dose is defined as the dose which controls the probability that R 0 < 1 and this can be computed by use of a MCMC algorithm. In section 4, a detailed analysis of the ALBI clinical trial is presented. In this trial, patients received different treatments or doses (patients in the third arm shifted treatment and some changed their dose) allowing us to study the predictive ability of the model. In section 5, we present a simulation study of the proposed strategy. The posterior distribution of the parameters is used as a prior for a new patient whose data are generated from the model. We examine the sensitivity of the method to misspecification of the prior. A conclusion and perspectives are given in section 6.
Models of interaction between HIV and immune system
2.1 Mathematical models Perelson et al. (1996) proposed a three-dimensional ODE system featuring uninfected CD4 + Tcells, infected CD4 + T-cells (T * ) and viruses (V ) concentrations. We shall work with an extension of this model called the "activated cells model", which distinguishes among uninfected cells those which are quiescent (Q) and those which are activated (T ). This model has been shown to fit the ALBI trial data much better (Commenges et al., 2008) . The definition of the parameters can be found in Table 1. [ Table 1 about here.]
The model can be written as:
The basic reproductive number R 0 (Gran et al., 2008 ) is given by:
If R 0 is lower than one, the only equilibrium point is the trivial one with V = 0, otherwise the trivial equilibrium is unstable and after introduction of the virus, the system stabilizes to a nontrivial equilibrium with V > 0 (see the formula in Web Appendix A ).
where φ l is the intercept, z i l and ω i l are the vectors of (possibly time-dependent) explanatory variables associated to the fixed and random effects respectively of the l th biological parameter.
The β l are vectors of regression coefficients associated to the fixed effects; u i is the individual vector of random effects. We assume u i ∼ N (0, Σ) with Σ a diagonal matrix.
Specifically, in the following we shall use as explanatory variable only the treatments doses
, where j is the treatment index. In the application there are two treatments (j = 1, 2); for sake of simplicity, we present the theory for only one treatment. We assume that the treatment acts by diminishing the infectivity (this is indeed the case for the reverse transcriptase inhibitors used in the application). The model for the infectivity parameter is assumed to be:
with β < 0 and where ψ(.) is a known increasing positive "pharmaco-dynamic" function. We assume in addition ψ(0) = 0 and ψ(.) unbounded.
Let X = (Q, T, T * , V ) in model (1). We used g 1 (X) = log 10 (V ) and g 2 (X) = (Q + T + T * ) 0.25 as transformations to achieve normality and homoscedasticity of measurement error distributions (Thiébaut et al., 2003) is a one-to-one function strictly decreasing with the dose. Thus, for any given ξ i , a unique critical dose exists. We obtain the critical dose, d crit (ξ i ) from (2) and (4):
Since C(., .) is increasing in its second argument, the optimal dose cannot be higher than d crit (ξ i ).
If C(., .) rises very sharply in its first argument, the optimal dose will be close to d crit (ξ i ). If C(x, y) presents a discontinuity in x = 0, the optimal dose is d crit (ξ i ). This is a reasonable requirement from the medical point of view: d crit (ξ i ) is the minimum dose which achieves virus extinction (in practice, a very low viral load). This relieves us from the burden of specifying a cost function which would weigh the toxicity and the efficiency of the drug in an arbitrary way.
3.2 Unknown parameters: controlling the probability that R 0 < 1
In practice the values of the parameters of a particular subject are unknown. We have however a certain amount of knowledge about ξ i . We make observations of both viral load and CD4 count at times before and after the initiation of the control strategy: t 0 , t −1 , t −2 ..., and t 1 , t 2 , ... respectively; this gives essentially information about the values of the random effects u i for this subject. Given
opt , the readjusted optimum dose, as the minimum dose which gives a high posterior probability (ω) that R 0 is below 1:
We may take ω = 90%; in the following, we write d
opt for the optimal dose at time t k . R 0 is a decreasing one-to-one function, thus, d t k opt is unique. We denote by ξ i * the true parameters value for patient i and d crit (ξ i * ) his critical dose. If we assume that the information increases in time so that Doob's consistency theorem can be applied (Van der Vaart, 2000) , d
t k opt will tend to the critical dose (see Web Appendix B for the proof ):
We have that P
the ω-quantile of the posterior distribution of d crit (ξ i ) which can be computed by MCMC using formula (6). 4. Dose effect and predictive ability in the ALBI trial
The ALBI trial
We use the data of the ALBI ANRS 070 trial (Molina et al., 1999) . In this three arms controlled trial, 151 antiretroviral-naive patients (with viral loads between 10,000 and 100,000 copies/mL and CD4 counts greater than 200 cells/mm 3 ) received 24 weeks of treatment. The 51 patients from arm 1, received the d4T+ddI treatment, that is stavudine (d4T) / didanosine (ddI) whose dosage depended on their weight; d4T 250mg plus ddI 60mg for patients less than 60kg, otherwise d4T
400mg plus ddI 80mg. For arm 2, 51 patients received the AZT+3TC treatment, that is 500mg of zidovudine (AZT) and 300mg of lamivudine (3TC). The 49 patients from arm 3, the switch arm, received the d4T+ddI treatment for 12 weeks followed by AZT+3TC, with the same doses as in arm 1 and 2. Blood samples were collected every 4 weeks until 24 weeks. CD4 counts and viral loads (with a lower quantification limit of 50 copies/mL) were measured. Two patients dropped out before the first blood sample collection time, so 149 patients were available for the analysis. For each patient, changes in dose were either self-reported or declared by the clinician. Twenty-seven patients (18%) changed their doses during the trial; some of them even interrupted the treatment during a period of time. Molina et al. (1999) found that the d4T+ddI treatment was significantly better than the AZT+3TC treatment in an intent-to-treat analysis.
Model for the ALBI trial
We performed a thorough analysis of the ALBI trial using the "activated cells model", taking into account all the complexities of the design and the doses actually taken by the patients. Doses were included in the analysis, by considering treatment as a time-varying covariate. We took into account the doses of the two ALBI treatments, denoted {d ). We constructed an indicator of the doses for treatment j = 1 (d4T+ddI) or 2 (AZT+3TC) as:
Moreover, we smoothed the dose indicators by taking the mean of the three doses taken in previous days, as this provided a better fit. Therefore, the dose indicator for treatment j of subject i at time t can be written:
As for the choice of ψ in (4), we first tried a linear function, but this achieved a poor fit of the data. We obtained a much better fit with power functions, with a power around 0.1. However, such a simple power function does not have an acceptable shape in the sense that the effect is still high for very low doses (for which we had no data). We tried sigmoid functions as in Shen et al. (2008) but this yielded shapes very similar to the power functions. To overcome this problem we constructed a function which was a power function in the range where information was available [0.6; 1], connected to zero by a linear function. Finally the "pharmaco-dynamical" function for patient i, treatment j at time t was:
We also tried to introduce the weights of the subjects as explanatory variable but did not find any effect of it; so these results are not shown.
Elicitation of a prior, algorithm and posterior
We denote by
) the vector of the parameters. Here, φ=(φ l , l=1. . . 9), appearing in (3), is the vector of the nine baseline biological parameters and β the two-dimensional vector of regressors for treatment doses. There are also three standard deviations of random effects (on α, λ and µ T * as suggested in Guedj et al. (2007) ) and the two standard deviations of errors measurements.
Normal independent priors were assumed for the components of φ with expectation and variance = log(10) = 2.3. For the effects of the treatment doses we also assumed normal priors with expectation corresponding to dividing the infectivity by 3 for the standard dose, and standard deviation equals to about the third of the absolute value of this expectation: this expresses the fact that it is unlikely that treatments increase the infectivity while yielding rather weakly informative priors. The priors did not value one treatment over the other. Half-Cauchy priors were taken for the variance of the random effects, as recommended by Gelman (2006) . For the variances of the measurement errors, conventional Jeffreys' improper non-informative priors were taken. In view of the complexity of the problem MCMC methods would be too time-consuming and the INLA method (Approximate Bayesian Inference for Latent Gaussian Models) (Rue et al., 2009) can not be applied to this problem. We turned to a normal approximation of the posterior which is justified by the Bernstein-Von Mises Theorem ( Van der Vaart, 2000) . Numerically, this amounts to compute the maximum a posteriori estimator (MAP); this is identical to penalized likelihood maximization. Specifically, the function that must be maximized is pl = L − J(θ), where the penalty term J(θ) is:
where E 0 and var 0 stand for the means and variances of the priors. Here, L is the log likelihood which is described in Guedj et al. (2007) . The maximization (or rather the minimization of −pl)
can be done using the algorithm described in Guedj et al. (2007) , modified to take into account the penalty brought by the prior. This algorithm uses the so-called RVS algorithm which approximates the Hessian using first derivatives. For penalized likelihood, the way the Hessian is approximated must be modified as described in section 4.5 of Commenges et al. (2006) . There is however a sign error in the original version. The correct formula for the Hessian of −pl in θ k (at iteration k) is:
where U (θ k ) = − ∂pl ∂θ θ k and the
∂θ 2 (here a diagonal matrix with positive diagonal) generally improves the condition number of the approximate Hessian. G(θ k ) is close to − ∂ 2 pl ∂θ 2 (θ k ) near the maximum. It is generally easy to compute
We evaluated κ d in (8) by profile likelihood, leading to κ d = 0.13. For other parameters, the posterior was approximated by a normal distribution with expectation given by the MAP and variance given by the inverse of the approximation of the Hessian of −pl (9). We present their means and standard deviations of posteriors in table 2.
[ Table 2 about here.]
Finally, we checked reproducibility by starting from 10 different initial values drawn at random at one standard deviation from the mean of the prior. The algorithm converged toward the same region obtaining the same 2 significant digits for the standard deviations of measurement errors and main random effect, one significant digit for most other parameters exceptπ,μ Q andμ P for which we only had the order of magnitude. This is probably due to lack of practical identifiably:
actually, predictions are not impacted by this relative lack of precision. In Web Appendix C we show that the fits for three stopping points with rather different values ofπ,μ Q andμ P are nearly indistinguishable. Since we use the model essentially for prediction, the problem is not too severe.
Results: predictive ability for treatment change
The ALBI design offers a very good opportunity to assess the predictive ability of our model, especially thanks to the switch arm. We can use the first period to assess the random effects for these patients and then predict how they react to the next treatment. We selected patients from the switch arm in an objective manner: we took them at the quartile values of the distribution of the viral load at the end of the study. We computed the MAP estimates removing these patients.
Then, we estimated the parameters with random effects thanks to a Parametric Empirical Bayes (PEB) procedure (Kass and Steffey, 1989 ) based on the first 12 weeks; viral loads and CD4 counts were computed for the value of the parameters using MAP estimates for fixed effects and PEB for parameters with random effects, taking into account the adherence for the remaining 12
weeks. Using notations in (5), we also computed a 95% "measurement error predictive interval" as
For space concern, we only present the median patient, but predictions for Q 1 and Q 3 patients at quartiles are available in Web Appendix D, others on request. Figure 2 presents the viral load and the total CD4 count with a fit in the first 12 weeks and predictions for the last 12 weeks after the treatment switch. One can see that we are able to predict quite well the viral load rebound after the treatment change (because the AZT+3TC treatment is less efficient).
[ Figure 2 about here.]
Results: predictive ability for dose change
We selected analyzed patients in an objective manner among the 27 patients with dose changes:
we took those at each quartile values in function of the distribution of the viral load at the end of the study. We estimated again all the parameters excluding this new subset of patients and did step-by-step prediction. Each time we had an additional observation, we updated the knowledge about random effect and computed the predicted value taking into account the reported adherence.
For sake of illustration, we present a patient who particularly well filled his adherence information and who had a large range of behaviors (drug dose reduction, stop, switch...). Figure   3 presents predicted of viral loads and total CD4 counts for each time taking into account the increase of information in time. The 95% "measurement error predictive interval" is represented.
Predictions taking into account drugs doses are much better than the IIT fits. [ Figure 3 about here.]
Simulation study for dose optimisation

Principle of the data simulation
In this section, we aim at analyzing the efficiency of our drug dose reduction algorithm in term of precision and safety (recommended doses should be higher than critical doses). Data were simulated using the MAP estimates from the analysis of the ALBI trial (Table 2 ). We simulated samples of 100 patients (n). Parameters with random effects, α, µ T * and λ were drawn from the multi-normal Gaussian posterior for every patient. Fixed parameters were drawn with the constraint (θ−θ) T G(θ)(θ−θ) = 1 and were the same for all the patients of a sample. We only selected patients who had a baseline R 0 (that is without treatment) higher than 1 and a critical dose lower than the standard dose; thus, we excluded long-term nonprogressors and only kept patients needing a dose reduction. We assumed a plausible observation schedule: observation times were at 0, 7 and 14 days whereas dose readjustments were performed every 15 days. The initial dose was taken as the reference, d 0 = 1. We simulated the viral loads and CD4 counts with measurement errors variances equal to (0.45) 2 and (0.2) 2 (Table 2) . Finally, as ALBI treatments are under-efficient compared to those given in 2011, we took a treatment effect equal to twice the MAP estimate of treatment effect for d4T+ddI (β 2 ), that is β = −2.06.
Illustration of the monitoring method
We ran the control strategy algorithm described in section 3.2 with a burn-in phase consisting in a 100 000 updates, a sampling phase of 50 000 updates, d max = 2 and ω = 90%. All the nine biological parameters were updated even if significant updates were only noticeable for parameters with random effects. It never recommended a dose greater than d max .
We first present the results for a particular patient drawn at random as visual illustration (10 updates were performed). His critical dose was 0.306. We can see on figure 4 (left) that at the first readjustment time we could advise a reduction by more than 55% of the dose given to the patient.
It is noticeable that the final dose was close to the critical dose. Moreover this result was obtained while remaining above the critical dose during the tuning period. Furthermore, we can check on figure 4 (right) that neither the viral load nor the CD4 count are impacted by drug reduction.
[ Figure 4 about here.] Table 3 presents the Mean Square Errors (MSE) between the optimal dose and the critical dose for each readjustment time computed as:
2 , together with the percentage of doses lower than the critical dose for the patient and the percentage of doses greater than d max . In a well-specified model, the MSE decreases while information about the patient increases and we effectively control the probability to give a dose below the critical dose.
Sensitivity analysis and a safer monitoring method
We performed a sensitivity analysis to evaluate the robustness of our control strategy in misspecified models. First, we investigated the effect of priors misspecification. In the same fashion as in part 5.1, we simulated samples of 100 patients with parameters such that (θ −θ) T G(θ)(θ −θ) = k, k = 1.5, 2, 2.5, 3 and 5. For each k, 10 different samples were taken in order to explore different profiles of prior misspecification. This extensive simulation study was made possible by using parallel computing. Results are presented in table 3. MSE were good up to k = 2.5 but the percentage of d t k opt < d crit reached 31% in average at the fifth readjustment. To fix this problem, we propose to add a safety margin to the readjusted dose. We focused on k=2 since priors should not be too badly specified if patients come from the same population as in ALBI trial. The value of the safety margin was determined such that our key proposition ∀k ∈ 0..5, P F i hold in the worst simulated case for k=2. We ran again the control procedure, applying the safety margin, over a new validation sample of 1000 patients with misspecified priors. Table 3 shows that MSE are increased but are still reasonable while, as expected, the percentage of d
smaller than 10%.
[ Table 3 about here.]
To finish, we tried a misspecified model. Data were generated from a "productive cell model"
(Drylewicz et al., 2010) which has 5 compartments instead of 4. To do so, we took a "productive cell model" with the same equilibrium state as in the "activated cell model". Productive cell production rate was fixed at -0.12, the estimates found by Drylewicz et al. (2010) . For all the readjustment times, the percentage of optimal doses lower than the critical dose was always lower than 10 %. MSE ranged from 1.21 at time t 1 to 0.12 at time t 5 .
Discussion
In this paper, we have proposed a method of dose individualization of HAART for HIV infected patients.
We have attempted to demonstrate its feasibility. First, a pharmaco-dynamic model was developed for the ALBI trial and we showed that it could be applied to real data. The model fitted the viral loads and CD4 counts data quite well, providing an in vivo estimation of the treatment efficacy. More importantly, the model had good prediction abilities. Then, the simulation study showed that when information is rich enough, the critical dose can be found in a rather small number of readjustments, while staying most of the time above the critical dose.
An issue is the possible lack of information due to left-censoring when the treatment is very effective. Then, Doob's consistency theorem invoked in section 3.2, would not apply. In that case, more intensive schedules and/or the measurements of more compartments would be needed. Other concerns could arise from model misspecification. A misspecification could lead to biased results and wrong recommendations. We have made a sensitivity analysis to test the robustness of the procedure to misspecification of the sampling distribution and to misspecification of the prior (which happens if the new patients are different from those used for defining the prior). In both cases the convergence toward the critical dose is slower but the procedure, which can be improved by using a safety margin, generally works.
A major issue is development of drug resistance. If this happens during the monitoring, then viral load will raise leading to higher recommended dose until we reach the maximum admissible dose. This is a failure of the treatment and another treatment has to be prescribed. The search of the optimal dose is relevant in a time period where no major resistance mutation develops.
We conclude that the use of such an adaptive scheme is to be further tested on more informative data (especially with well documented adherence); however, this work shows that dose individualization is possible. The further step would be to validate the procedure in a clinical trial before using it in clinical practice. Such a clinical trial would typically have two arms, one in which the proposed procedure of dose monitoring would be applied, the other in which standard clinical practice would be applied; the endpoints would be the doses given at the end of the trial, measures of adverse effects and the proportion of virological failures.
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